Identification of a novel PPARγ modulator with good anti-diabetic therapeutic index via structure-based screening, optimization and biological validation.
Biomed Pharmacother
; 154: 113653, 2022 Oct.
Article
en En
| MEDLINE
| ID: mdl-36942599
Palabras clave
(S)-VSP-77 (PubChem CID: 139267749); 3-Isobutyl-1-methylxanthine (PubChem CID: 3758); Anti-diabetic effects; Benzozodihydropyran derivatives; Decanoic acid (PubChem CID: 2969); Dexamethasone (PubChem CID: 5743); Dimethyl sulfoxide (PubChem CID: 679); Fenticonazole nitrate (PubChem CID: 51754); Glucose (PubChem CID: 5793); Insulin (PubChem CID: 16131098); PPARγ-Ser273 phosphorylation; Pioglitazone (PubChem CID: 4829); Rosiglitazone (PubChem CID: 77999); SB-VHTS; SPPARγM
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
PPAR gamma
Tipo de estudio:
Diagnostic_studies
/
Screening_studies
Idioma:
En
Revista:
Biomed Pharmacother
Año:
2022
Tipo del documento:
Article
Pais de publicación:
Francia